fingolimod mylan
mylan ireland limited - fingolimod stutt og long-term - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 og 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
acetylcystein mylan freyðitafla 200 mg
mylan ab* - acetylcysteinum inn - freyðitafla - 200 mg
klomipramin mylan filmuhúðuð tafla 25 mg
mylan ab* - clomipraminum hýdróklóríð - filmuhúðuð tafla - 25 mg
klomipramin mylan filmuhúðuð tafla 10 mg
mylan ab* - clomipraminum hýdróklóríð - filmuhúðuð tafla - 10 mg
gabapentin mylan hart hylki 300 mg
mylan ab* - gabapentinum inn - hart hylki - 300 mg
gabapentin mylan hart hylki 400 mg
mylan ab* - gabapentinum inn - hart hylki - 400 mg
lidokain mylan (lidokain farmaplus) stungulyf, lausn 10 mg/ml
mylan ireland limited - lidocainum hýdróklóríð - stungulyf, lausn - 10 mg/ml
lidokain mylan (lidokain farmaplus) stungulyf, lausn 20 mg/ml
mylan ireland limited - lidocainum hýdróklóríð - stungulyf, lausn - 20 mg/ml
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klópídógrel hýdróklóríð - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - blóðþurrðandi lyf - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
talmanco (previously tadalafil generics)
viatris limited - tadalafil - háþrýstingur, lungnabólga - Þvaglát - talmanco er ætlað í fullorðnir fyrir meðferð lungum slagæð háan blóðþrýsting (pah) flokkast sem hagnýtur ii og iii, til að bæta æfing getu. verkun hefur verið sýnd í sjálfvakta pah (ipah) og í pah í tengslum við krabbameinsvaldandi sjúkdóma.